The Impact of Chronic Kidney Disease on Peripheral Artery Disease and Peripheral Revascularization

References

• Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl. 2013;91–111. doi:10.1038/kisup.2012.67
   Google Scholar
• De Nicola L, Provenzano M, Chiodini P, et al. Independent role of underlying kidney disease on renal prognosis of patients with chronic kidney disease under nephrology care. PLoS One. 2015;10(5):e0127071. doi:10.1371/journal.pone.0127071
   PubMed Web of Science ®Google Scholar
• Provenzano M, Garofalo C, Chiodini P, et al. Role of proteinuria in clinical research: for each old-answer, a new key-question. Recent Prog Med. 2020;111(2):74–81.
   PubMedGoogle Scholar
• Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–180. doi:10.1016/S0140-6736(11)60178-5
   PubMed Web of Science ®Google Scholar
• Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. a collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331–1340. doi:10.1038/ki.2010.550
   PubMed Web of Science ®Google Scholar
• Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–525. doi:10.1016/S2213-8587(15)00040-6
   PubMed Web of Science ®Google Scholar
• Ballew SH, Matsushita K. Cardiovascular risk prediction in CKD. Semin Nephrol. 2018;38(3):208–216. doi:10.1016/j.semnephrol.2018.02.002
   PubMed Web of Science ®Google Scholar
• Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840– e878. doi:10.1161/CIR.0000000000000664
   PubMed Web of Science ®Google Scholar
• Provenzano M, Coppolino G, Faga T, et al. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer. Rev Cardiovasc Med. 2019;20(4):209–220.
   PubMed Web of Science ®Google Scholar
• Pena MJ, Stenvinkel P, Kretzler M, et al. Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. Kidney Int Suppl. 2017;7(2):107–113. doi:10.1016/j.kisu.2017.07.005
   Web of Science ®Google Scholar
• Hayatsu Y, Ruel M, Sun LY. Renal insufficiency and severe coronary artery disease: should coronary artery bypass grafting, off-pump coronary artery bypass grafting or percutaneous coronary intervention be performed? Curr Opin Cardiol. 2019;34(6):645–649. doi:10.1097/HCO.0000000000000687
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Mokdad AH, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567–581. doi:10.1016/j.kint.2018.04.011
   PubMed Web of Science ®Google Scholar
• De Nicola L, Donfrancesco C, Minutolo R, et al. Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey. Nephrol Dial Transplant. 2015;30(5):806–814. doi:10.1093/ndt/gfu383
   PubMed Web of Science ®Google Scholar
• Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663. doi:10.1001/archinte.164.6.659
   PubMed Web of Science ®Google Scholar
• Patel UD, Young EW, Ojo AO, et al. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis. 2005;46(3):406–414. doi:10.1053/j.ajkd.2005.05.027
   PubMed Web of Science ®Google Scholar
• Van Zuilen AD, Van der Tweel I, Blankestijn PJ, et al. Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]. Trials. 2006;7(1):8. doi:10.1186/1745-6215-7-8
   PubMed Web of Science ®Google Scholar
• Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis. 2001;38(3):537–546. doi:10.1053/ajkd.2001.26850
   PubMed Web of Science ®Google Scholar
• Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American study of kidney disease and hypertension (AASK) trial. Am J Kidney Dis. 2006;48(5):739–751. doi:10.1053/j.ajkd.2006.08.004
   PubMed Web of Science ®Google Scholar
• Provenzano M, Chiodini P, Minutolo R, et al. Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics. Nephrol Dial Transplant. 2020;35(1):138–147.
   PubMed Web of Science ®Google Scholar
• Thomas B, Matsushita K, Abate KH, et al. Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol. 2017;28(7):2167–2179. doi:10.1681/ASN.2016050562
   PubMed Web of Science ®Google Scholar
• Theilade S, Lajer M, Jorsal A, et al. Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. Diabet Med. 2012;29(8):990–994. doi:10.1111/j.1464-5491.2012.03633.x
   PubMed Web of Science ®Google Scholar
• Provenzano M, Coppolino G, De Nicola L, et al. Unraveling cardiovascular risk in renal patients: a new take on old tale. Front Cell Dev Biol. 2019;3(7):314. doi:10.3389/fcell.2019.00314
   Web of Science ®Google Scholar
• Gerhard-Herman MD, Gornik HL, Barrett C, et al. Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2017;135(12):e726–e779.
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–67.
   PubMed Web of Science ®Google Scholar
• Berger JS, Hochman J, Lobach I, et al. Modifiable risk factor burden and the prevalence of peripheral artery disease in different vascular territories. J Vasc Surg. 2013;58(3):673–81.e1. doi:10.1016/j.jvs.2013.01.053
   PubMed Web of Science ®Google Scholar
• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National health and nutrition examination survey, 1999–2000. Circulation. 2004;110(6):738–743. doi:10.1161/01.CIR.0000137913.26087.F0
   PubMed Web of Science ®Google Scholar
• Creager MA. The crisis of vascular disease and the journey to vascular health: presidential address at the American Heart Association 2015 Scientific Sessions. Circulation. 2016;133(24):2593–2598. doi:10.1161/CIR.0000000000000434
   PubMed Web of Science ®Google Scholar
• O’Hare AM, Vittinghoff E, Hsia J, et al. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the heart and estrogen/progestin replacement study (HERS). J Am Soc Nephrol. 2004;15(4):1046. doi:10.1097/01.ASN.0000119574.27772.FD
   PubMed Web of Science ®Google Scholar
• Wattanakit K, Folsom AR, Selvin E, et al. Kidney function and risk of peripheral arterial disease: results from the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18(2):629. doi:10.1681/ASN.2005111204
   PubMed Web of Science ®Google Scholar
• Matsushita K, Ballew SH, Coresh J, et al. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2017;5(9):718–728. doi:10.1016/S2213-8587(17)30183-3
   PubMed Web of Science ®Google Scholar
• Staplin N, Haynes R, Herrington WG, et al. Smoking and adverse outcomes in patients with CKD: the study of heart and renal protection (SHARP). Am J Kidney Dis. 2016;68(3):371–380. doi:10.1053/j.ajkd.2016.02.052
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Perkovic V; Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;347:f5680.
   PubMed Web of Science ®Google Scholar
• Jaar BG, Plantinga LC, Astor BC, et al. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chronic Kidney Dis. 2007;14(3):304–313. doi:10.1053/j.ackd.2007.04.005
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Dellegrottaglie S, Furniss AL, et al. Peripheral arterial disease in patients with end-stage renal disease: observations from the dialysis outcomes and practice patterns study (DOPPS). Circulation. 2006;114(18):1914–1922. doi:10.1161/CIRCULATIONAHA.105.607390
   PubMed Web of Science ®Google Scholar
• Bourrier M, Ferguson TW, Embil JM, et al. Peripheral artery disease: its adverse consequences with and without CKD. Am J Kidney Dis. 2020;75(5):705–712. doi:10.1053/j.ajkd.2019.08.028
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338–350. doi:10.1161/CIRCULATIONAHA.117.032235
   PubMed Web of Science ®Google Scholar
• Hishida M, Menez S, Matsushita K. Peripheral artery disease in CKD: anatomically peripheral but clinically central. Am J Kidney Dis. 2020;75(5):687–689. doi:10.1053/j.ajkd.2019.10.006
   PubMed Web of Science ®Google Scholar
• Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517–538. doi:10.1016/S0741-5214(97)70045-4
   PubMed Web of Science ®Google Scholar
• Hardman RL, Jazaeri O, Yi J, et al. Overview of classification systems in peripheral artery disease. Semin Intervent Radiol. 2014;31:378–388.
   PubMed Web of Science ®Google Scholar
• Mills JL Sr, Conte MS, Armstrong DG, et al.; Society for Vascular Surgery Lower Extremity Guidelines Committee The society for vascular surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59(1):220–34.e1–2. doi:10.1016/j.jvs.2013.08.003.
   Web of Science ®Google Scholar
• Farchioni L, Gennai S, Giuliani E, et al. A prognostic risk score for major amputation in dialysis patients with chronic limb-threatening ischemia after endovascular revascularization. Int Angiol. 2021;40(3):206–212; PMID: 33660496. doi: 10.23736/S0392-9590.21.04523-5
   PubMed Web of Science ®Google Scholar
• Arinze NV, Gregory A, Francis JM, et al. Unique aspects of peripheral artery disease in patients with chronic kidney disease. Vasc Med. 2019;24(3):251–260. doi:10.1177/1358863X18824654
   PubMed Web of Science ®Google Scholar
• Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2017;135(12):e726–e779.
   PubMed Web of Science ®Google Scholar
• Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956–965. PMID: 20828648. doi:10.1016/j.jacc.2010.02.068
   PubMed Web of Science ®Google Scholar
• Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3):609S–626S. PMID: 15383487. doi:10.1378/chest.126.3_suppl.609S
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192; PMID: 21663949; PMCID: PMC3145073. doi: 10.1016/S0140-6736(11)60739-3
   PubMed Web of Science ®Google Scholar
• De Nicola L, Provenzano M, Chiodini P, et al.; SIR-SIN study group. Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: multicenter prospective study in Italy. Nutr Metab Cardiovasc Dis. 2015; 25(8):756–762. doi:10.1016/j.numecd.2015.04.001. PMID: 26026213.
   PubMed Web of Science ®Google Scholar
• Mazari FA, Gulati S, Rahman MN, et al. Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Ann Vasc Surg. 2010;24(1):69–79. doi:10.1016/j.avsg.2009.07.005
   PubMed Web of Science ®Google Scholar
• Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother. 2001;35(1):48–56.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314–1319. doi:10.1016/S0002-9149(02)02869-2
   PubMed Web of Science ®Google Scholar
• Bracale UM, Giribono AM, Spinelli D, et al. Long-term results of endovascular treatment of TASC C and D aortoiliac occlusive disease with expanded polytetrafluoroethylene stent graft. Ann Vasc Surg. 2019;56:254–260. doi:10.1016/j.avsg.2018.07.060
   PubMed Web of Science ®Google Scholar
• Tendera M, Aboyans V; European Stroke Organisation. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–2906.
   PubMed Web of Science ®Google Scholar
• Ambur V, Park P, Gaughan JP, et al. The impact of chronic kidney disease on lower extremity bypass outcomes in patients with critical limb ischemia. J Vasc Surg. 2019;69(2):491–496. doi:10.1016/j.jvs.2018.05.229
   PubMed Web of Science ®Google Scholar
• Biancari F, Salenius JP, Heikkinen M, et al. Risk-scoring method for prediction of 30-day postoperative outcome after infrainguinal surgical revascularization for critical lower-limb ischemia: a Finnvasc registry study. World J Surg. 2007;31(1):217–25;discussion 226–7. doi:10.1007/s00268-006-0242-y
   PubMed Web of Science ®Google Scholar
• Schanzer A, Mega J, Meadows J, et al. Risk stratification in critical limb ischemia: derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. J Vasc Surg. 2008;48(6):1464–1471. doi:10.1016/j.jvs.2008.07.062
   PubMed Web of Science ®Google Scholar
• Farber A. Chronic limb-threatening ischemia. N Engl J Med. 2018;379(2):171–180. doi:10.1056/NEJMcp1709326
   PubMed Web of Science ®Google Scholar
• Leskinen Y, Salenius JP, Lehtimäk T, et al. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40(3):472–479. doi:10.1053/ajkd.2002.34885
   PubMed Web of Science ®Google Scholar
• United States Renal Data System. Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases;2018.
   Google Scholar
• Owens CD, Ho KJ, Kim S, et al. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg. 2007;45(5):944–952. doi:10.1016/j.jvs.2007.01.025
   PubMed Web of Science ®Google Scholar
• Zlatanovi P, Koncar I, Dragas M, et al. Combined impact of chronic kidney disease and contrast induced acute kidney injury on long-term outcomes in patients with acute lower limb ischaemia. Eur J Vasc Endovasc Surg. 2018;56(1):78–86. doi:10.1016/j.ejvs.2018.03.008
   PubMed Web of Science ®Google Scholar
• Ortmann J, Gahl B, Diehm N, et al. Survival benefits of revascularization in patients with critical limb ischemia and renal insufficiency. J Vasc Surg. 2012;56(3):737–45.e1. doi:10.1016/j.jvs.2012.02.049
   PubMed Web of Science ®Google Scholar
• Kumada Y, Aoyama T, Ishii H, et al. Long-term outcome of percutaneous transluminal angioplasty in chronic haemodialysis patients with peripheral arterial disease. Nephrol Dial Transplant. 2008;23(12):3996–4001. doi:10.1093/ndt/gfn378
   PubMed Web of Science ®Google Scholar
• Graziani L, Silvestro A, Bertone V, et al. Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral artery disease. Nephrol Dial Transplant. 2007;22(4):1144–1149. doi:10.1093/ndt/gfl764
   PubMed Web of Science ®Google Scholar
• O’Hare AM, Bertenthal D, Sidawy AN, et al. Renal insufficiency and use of revascularization among a national cohort of men with advanced lower extremity peripheral arterial disease. Clin J Am Soc Nephrol. 2006;1(2):297–304. doi:10.2215/CJN.01070905
   PubMed Web of Science ®Google Scholar
• Lüders F, Bunzemeier H, Engelbertz C, et al. CKD and acute and long-term outcome of patients with peripheral artery disease and critical limb ischemia. Clin J Am Soc Nephrol. 2016;11:216–222.
   PubMed Web of Science ®Google Scholar
• Kumada Y, Nogaki H, Ishii H, et al. Clinical outcome after infrapopliteal bypass surgery in chronic hemodialysis patients with critical limb ischemia. J Vasc Surg. 2015;61(2):400–404. doi:10.1016/j.jvs.2014.09.007
   PubMedGoogle Scholar
• Patel VI, Mukhopadhyay S, Guest JM, et al. Impact of severe chronic kidney disease on outcomes of infrainguinal peripheral arterial intervention. J Vasc Surg. 2014;59(2):368–375. doi:10.1016/j.jvs.2013.09.006
   PubMed Web of Science ®Google Scholar
• Andreucci M, Faga T, Serra R, et al. Update on the renal toxicity of iodinated contrast drugs used in clinical medicine. Drug Healthc Patient Saf. 2017;22(4):25–37. doi:10.2147/DHPS.S122207
   Google Scholar
• Andreucci M, Faga T, Pisani A, et al. Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. ScientificWorldJournal. 2014;2014:823169. doi:10.1155/2014/823169
   PubMedGoogle Scholar
• Andreucci M, Faga T, Pisani A, et al. Acute kidney injury by radiographic contrast media: pathogenesis and prevention. Biomed Res Int. 2014;2014:362725.
   PubMed Web of Science ®Google Scholar
• O’Hare AM, Feinglass J, Sidawy AN, et al. Impact of renal insufficiency on short-term morbidity and mortality after lower extremity revascularization: data from the department of veterans affairs’ national surgical quality improvement program. J Am Soc Nephrol. 2003;14(5):1287–1295. doi:10.1097/01.ASN.0000061776.60146.02
   PubMed Web of Science ®Google Scholar
• Provenzano M, De Nicola L, Pena MJ, et al. Precision nephrology is a non-negligible state of mind in clinical research: remember the past to face the future. Nephron. 2020;144(10):463–478. doi:10.1159/000508983
   PubMed Web of Science ®Google Scholar
• Andreucci M, Provenzano M, Faga T, et al. Aortic aneurysms, chronic kidney disease and metalloproteinases. Biomolecules. 2021;11(2):194. doi:10.3390/biom11020194
   PubMed Web of Science ®Google Scholar
• Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015;39(1–3):84–92. doi:10.1159/000368940
   PubMed Web of Science ®Google Scholar
• Malhotra R, Katz R, Jotwani V, et al. Urine markers of kidney tubule cell injury and kidney function decline in SPRINT Trial participants with CKD. Clin J Am Soc Nephrol. 2020;15(3):349–358. doi:10.2215/CJN.02780319
   PubMed Web of Science ®Google Scholar
• Provenzano M, Rivoli L, Garofalo C, et al. Renal resistive index in chronic kidney disease patients: possible determinants and risk profile. PLoS One. 2020;15(4):e0230020. doi:10.1371/journal.pone.0230020
   PubMed Web of Science ®Google Scholar
• Gorriz JL, Molina P, Cervero´n MJ, et al. Vascular calcification in patients with non dialysis CKD over 3 years. Clin J Am Soc Nephrol. 2015;10(4):654–666. doi:10.2215/CJN.07450714
   PubMed Web of Science ®Google Scholar
• Perticone M, Maio R, Sciacqua A, et al. Serum phosphorus levels are associated with endothelial dysfunction in hypertensive patients. Nutr Metab Cardiovasc Dis. 2016;26(8):683–688. doi:10.1016/j.numecd.2016.02.003
   PubMed Web of Science ®Google Scholar
• Provenzano M, Andreucci M, Garofalo C, et al. The association of matrix metalloproteinases with chronic kidney disease and peripheral vascular disease: a light at the end of the tunnel? Biomolecules. 2020;10(1):154. doi:10.3390/biom10010154
   PubMed Web of Science ®Google Scholar
• Hu Y, Ivashkiv LB. Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. J Immunol. 2006;176(10):6022–6033. doi:10.4049/jimmunol.176.10.6022
   PubMed Web of Science ®Google Scholar
• Li Q, Park PW, Wilson CL, et al. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 2002;111(5):635–646. doi:10.1016/S0092-8674(02)01079-6
   PubMed Web of Science ®Google Scholar
• Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol. 2011;179(4):1733–1745. doi:10.1016/j.ajpath.2011.06.041
   PubMed Web of Science ®Google Scholar
• Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA. 2004;101(15):5634–5639. doi:10.1073/pnas.0401060101
   PubMed Web of Science ®Google Scholar
• Sritharan K, Essex D, Sandison A, et al. Membrane Type-1 matrix metalloproteinase: a key player in carotid plaque instability and symptomatic carotid atherosclerotic disease. Br J Surg. 2008;95:2.
   Google Scholar
• De Caridi G, Massara M, Spinelli F, et al. Matrix metalloproteinases and risk stratification in patients undergoing surgical revascularisation for critical limb ischaemia. Int Wound J. 2016;13(4):493–499. doi:10.1111/iwj.12464
   PubMed Web of Science ®Google Scholar
• Gondouin B, Cerini C, Dou L, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int. 2013;84(4):733–744. doi:10.1038/ki.2013.133
   PubMed Web of Science ®Google Scholar
• Yang K, Du C, Wang X, et al. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease associated thrombosis in mice. Blood. 2017;129(19):2667–2679. doi:10.1182/blood-2016-10-744060
   PubMed Web of Science ®Google Scholar
• Provenzano M, Andreucci M, De Nicola L, et al. The role of prognostic and predictive biomarkers for assessing cardiovascular risk in chronic kidney disease patients. Biomed Res Int. 2020;2020:2314128. doi:10.1155/2020/2314128
   PubMed Web of Science ®Google Scholar
• Provenzano M, Rotundo S, Chiodini P, et al. Contribution of predictive and prognostic biomarkers to clinical research on chronic kidney disease. Int J Mol Sci. 2020;21(16):5846. doi:10.3390/ijms21165846
   PubMed Web of Science ®Google Scholar
• Liabeuf S, Lenglet A, Desjardins L, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012;82(12):1297–1303. doi:10.1038/ki.2012.301
   PubMed Web of Science ®Google Scholar
• Nakano T, Ninomiya T, Sumiyoshi S, et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis. 2010;55(1):21–30. doi:10.1053/j.ajkd.2009.06.034
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Gansevoort RT. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin J Am Soc Nephrol. 2015;10(6):1079–1088. doi:10.2215/CJN.11511114
   PubMed Web of Science ®Google Scholar
• De Zeeuw D, Heerspink HJL. Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy. Nephrol Dial Transplant. 2020;35(Supplement_2):ii38–ii42. doi:10.1093/ndt/gfaa013
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937–1947.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi:10.1056/NEJMoa2025845
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa1515920
   PubMed Web of Science ®Google Scholar
• Provenzano M, Andreucci M, Garofalo C, et al. Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease. Expert Opin Investig Drugs. 2021;30(3):253–262. doi:10.1080/13543784.2021.1869720
   PubMed Web of Science ®Google Scholar
• Garimella PS, Hirsch AT. Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes. Adv Chronic Kidney Dis. 2014;21(6):460–471.
   PubMed Web of Science ®Google Scholar